# US 2022/0296710 A1 · Modular phage vector platform for sonodynamic therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0296710 A1
- Document ID: US20220296710A1
- Status: Published application
- Kind: A1
- Application number: 17/596,746
- Filed: 2020-06-26
- Published: 2022-09-22
- Earliest claimed: 2019-06-26
- Assignees: Alma Mater Studiorum - Università di Bologna
- Applicants: ALMA MATER STUDIORUM - Universita' di Bologna
- Inventors: Alberto Danielli; Matteo Calvaresi; Matteo Di Giosia; Andrea Cantelli; Francesco Starinieri; Michela Nigro; Edoardo Sarti
- Web page: https://patentgrep.com/patent/US20220296710A1

## CPC

- A61K 41/0033: {Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds (ultrasound therapy per se A61N7/00)}
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2795/14121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/14132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a phage or a composition that comprises it, wherein said phage expresses at least one specific recognition element and is furthermore conjugated with at least 300 molecules of a sonosensitiser. The invention further relates to the use of said phage in a sonodynamic therapy.

## Claims

### Claim 1

A phage expressing at least one specific recognition element that and is conjugated with at least 300 molecules of a sonosensitiser.

### Claim 2 (depends on 1)

The phage according to claim 1, wherein the sonosensitiser is selected from: Bacteriochlorin, Phthalocyanines, Pheophorbide A and B, Bacteriopheophorbide, Naphthalocyanine, BODIPY stains, Anthracycline, Tetracycline, Fluoroquinolones, Phenothiazine, Perylene, Perylenequinone, Curcumin, Quinones, Anthraquinones, Fullerenes, Endohedral Metallofullerenes, Acridines, Isoquinole alkaloids, Xanthenes, Porphyrins, Chlorins and Cyanine.

### Claim 3 (depends on 1)

The phage according to claim 1, wherein the sonosensitiser is selected from: a xanthen, a porfirin, a chlorin, a cyanine and combinations thereof.

### Claim 4 (depends on 3)

The phage according to claim 3, wherein the xanthen is selected from rose bengal, eosin, erythrosin B, fluorescein and rhodamine; the porphyirin is selected from protoporphyirin IX, hematoporphyirin, porfimer sodium and ATX-70; the chlorin is selected from chlorin e6, temoporfin and verteporfin; the cyanine is selected from cyanine IR-806, indocyanine green and cyanine IR-780, and combinations thereof.

### Claim 5 (depends on 1)

The phage according to claim 1, wherein said phage is conjugated with at least 400 sonosensitiser molecules.

### Claim 6 (depends on 1)

The phage according to claim 1, wherein the phage is selected from the M13 phage, fd phage, Ff phage, T4 and MS2 phage.

### Claim 7 (depends on 1)

The phage according to claim 1, wherein said specific recognition element is selected from: an antibody, a receptor, a protein, a peptide and combinations thereof.

### Claim 8 (depends on 1)

The phage according to claim 1, wherein said specific recognition element is selected from: EGFR, HER2+, EGFRvIII, CD99, GD2, fibronectin, bacterial fimbriae and flagella and a peptide binding to the outer membrane of Gram-negative bacteria.

### Claim at position 9

9-15. (canceled)

### Claim 16 (depends on 1)

The phage according to claim 1, wherein said phage is conjugated with at least 500 sonosensitizer molecules.

### Claim 17 (depends on 1)

The phage according to claim 1, wherein said phage is conjugated with at least 700 sonosensitizer molecules.

### Claim 18 (depends on 6)

The phage according to claim 6, wherein the phage is M13 phage.

### Claim 19 (depends on 1)

A method for treating a tumour comprising administering to a subject a phage according to claim 1 or a composition comprising a phage according to claim 1 further comprising excipients and/or additional substances and/or pharmaceutically accepted carriers.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said tumor is a malignant tumor.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the tumor is a tumor with overexpression of at least one structure selected from: EGFR, HER2+, EGFRvIII, fibronectin, CD99, GD2 and combinations thereof.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the phage is administered in association or in combination with at least one antitumoral.

### Claim 23 (depends on 19)

The method according to claim 19, wherein the phage is administered in association or in combination with ultrasound.

### Claim 24 (depends on 19)

The method according to claim 19, wherein the phage is administered in association or in combination with a surgical treatment.

### Claim 25 (depends on 19)

The method according to claim 19, wherein the phage is administered in association or in combination with a treatment of a malignant tumor.

### Claim 26 (depends on 19)

The method according to claim 19, wherein the phage is administered in before or after an operation to remove the malignant tumor.

### Claim 27 (depends on 1)

A method for treating an infection comprising administering to a subject a phage according to claim 1 or a composition comprising a phage according to claim 1 further comprising excipients and/or additional substances and/or pharmaceutically accepted carriers, wherein the infection is selected from a bacterial, viral or fungal infection.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the infection is a bacterial infection.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the phage is administered in association or in combination with at least one antibiotic.

### Claim 30 (depends on 27)

The method according to claim 27, wherein the phage is administered in association or in combination with ultrasound.
